C12N 2740/10041
Use of virus, viral particle or viral elements as a vector
C12N2740/10041 (Use of virus, viral particle or viral elements as a vector) appears on 264 US grants and 541 published applications in this corpus.
Search patents in C12N- Granted patents
- 264
- Published applications
- 541
- Assignees
- 309
- Inventors
- 1,155
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 6 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 5 | 0 |
| 2001 | 6 | 0 |
| 2002 | 4 | 9 |
| 2003 | 4 | 7 |
| 2004 | 7 | 10 |
| 2005 | 5 | 5 |
| 2006 | 2 | 3 |
| 2007 | 2 | 5 |
| 2008 | 2 | 4 |
| 2009 | 1 | 9 |
| 2010 | 7 | 10 |
| 2011 | 4 | 7 |
| 2012 | 2 | 9 |
| 2013 | 9 | 6 |
| 2014 | 4 | 13 |
| 2015 | 4 | 12 |
| 2016 | 8 | 23 |
| 2017 | 7 | 19 |
| 2018 | 14 | 26 |
| 2019 | 16 | 30 |
| 2020 | 17 | 41 |
| 2021 | 15 | 31 |
| 2022 | 20 | 54 |
| 2023 | 17 | 47 |
| 2024 | 18 | 57 |
| 2025 | 31 | 63 |
| 2026 | 25 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/10043Viral genome or elements thereof as genetic vectorIndexing code225
- C12N 2740/10042Virus or viral particle as vehicleIndexing code10
- C12N 2740/10045Special targeting system for viral vectorsIndexing code7
- C12N 2740/10044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code2
Recent patents
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- K562 universal antigen presenting cells and uses thereof15 Sep 2026US 12,734,239 B2Board of Regents, The University of Texas System
- T cell receptors recognizing R273C or Y220C mutations in P531 Sep 2026US 12,721,890 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition16 Jun 2026US 12,653,809 B2Nurix Therapeutics, Inc.
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Method for producing high-titer viral vector8 Oct 2026US 2026/0308534 A1Kaneka Corporation
- Anti-cancer treatments and methods of use thereof8 Oct 2026US 2026/0308535 A1
- Method for the production of bi-functional cells to treat neoplasia1 Oct 2026US 2026/0297162 A1Eir Biotherapies Srl
- Viral vectors for glioblastoma cell therapy24 Sep 2026US 2026/0284109 A1
- Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma24 Sep 2026US 2026/0285935 A1The Children’s Hospital of Philadelphia
Most cited
By later US patents
- Multispecific chimeric receptors174US 6,103,521 ACell Genesys, Inc. · 2000
- Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells159US 6,326,198 B1The Regents of the University of Michigan · 2001
- Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture146US 5,635,386 AThe Regents of the University of Michigan · 1997
- Methods, compositions and devices for growing human hematopoietic cells115US 5,605,822 AThe Regents of the University of Michigan · 1997
- Generation of neural precursor cell lines107US 5,580,777 AAmrad Corporation Limited · 1996